Last reviewed 2026-04-20 · How we verify

Hydroxythiospasmin (OXYSONIUM)

Phase 2 active Small molecule

Hydroxythiospasmin (generic name: OXYSONIUM) is a oxysonium drug. It is currently in Phase 2 development.

Oxysonium works by interacting with a specific molecular target to produce a therapeutic effect.

Hydroxythiospasmin, also known as Oxysonium, is a small molecule oxysonium drug with an unknown target. Its exact mechanism of action and approved indications are not well-documented. As a result, there is limited information available on its commercial status, safety considerations, or pharmacokinetic properties. Further research is needed to fully understand this compound. Its development and current ownership are also unclear.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	OXYSONIUM
Drug class	oxysonium
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and oxysonium is a key that fits into one of those locks. When it binds, it triggers a series of events that ultimately lead to a desired outcome, such as reducing inflammation or blocking a harmful process.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Hydroxythiospasmin CI brief — competitive landscape report
Hydroxythiospasmin updates RSS · CI watch RSS

Frequently asked questions about Hydroxythiospasmin

What is Hydroxythiospasmin?

Hydroxythiospasmin (OXYSONIUM) is a oxysonium drug.

How does Hydroxythiospasmin work?

Oxysonium works by interacting with a specific molecular target to produce a therapeutic effect.

What is the generic name of Hydroxythiospasmin?

OXYSONIUM is the generic (nonproprietary) name of Hydroxythiospasmin.

What drug class is Hydroxythiospasmin in?

Hydroxythiospasmin belongs to the oxysonium class. See all oxysonium drugs at /class/oxysonium.

What development phase is Hydroxythiospasmin in?

Hydroxythiospasmin is in Phase 2.

Drug class: All oxysonium drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing